Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease by Laetitia Francelle et al.
REVIEW ARTICLE
published: 26 September 2014
doi: 10.3389/fncel.2014.00295
Possible involvement of self-defense mechanisms in the
preferential vulnerability of the striatum in Huntington’s
disease
Laetitia Francelle1,2, Laurie Galvan1,2,3 and Emmanuel Brouillet1,2*
1 Neurodegenerative Disease Laboratory, Commissariat à l’Énergie Atomique et aux Énergies Alternatives, Direction des Sciences du Vivant, Institut d’Imagerie
BioMédicale, Molecular Imaging Research Center, Fontenay-aux-Roses, France
2 Centre National de la Recherche Scientifique - Commissariat à l’Énergie Atomique et aux Énergies Alternatives Unité de Recherche Associée 2210,
Fontenay-aux-Roses, France
3 Intellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior, Brain Research Institute,
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
Edited by:
Rosanna Parlato, Ulm University,
Germany
Reviewed by:
Jose R. Naranjo, Centro Nalcional de
Biotecnologia/Consejo Superior de
Investigaciones Cientificas, Spain
David Blum, Institut National de la
Santé et de la Recherche Médicale,
France
*Correspondence:
Emmanuel Brouillet,
Neurodegenerative Disease
Laboratory, Centre National de la
Recherche Scientifique - CEA Unité
de Recherche Associée 2210,
Molecular Imaging Research Center,
Institut d’Imagerie BioMédicale,
CEA, 18 Route du Panorama, BP 6,
92265 Fontenay-aux-Roses, France
e-mail: emmanuel.brouillet@cea.fr
HD is caused by a mutation in the huntingtin gene that consists in a CAG repeat
expansion translated into an abnormal poly-glutamine (polyQ) tract in the huntingtin
(Htt) protein. The most striking neuropathological finding in HD is the atrophy of the
striatum. The regional expression of mutant Htt (mHtt) is ubiquitous in the brain and
cannot explain by itself the preferential vulnerability of the striatum in HD. mHtt has
been shown to produce an early defect in transcription, through direct alteration of the
function of key regulators of transcription and in addition, more indirectly, as a result of
compensatory responses to cellular stress. In this review, we focus on gene products that
are preferentially expressed in the striatum and have down- or up-regulated expression
in HD and, as such, may play a crucial role in the susceptibility of the striatum to mHtt.
Many of these striatal gene products are for a vast majority down-regulated and more
rarely increased in HD. Recent research shows that some of these striatal markers have
a pro-survival/neuroprotective role in neurons (e.g., MSK1, A2A, and CB1 receptors)
whereas others enhance the susceptibility of striatal neurons to mHtt (e.g., Rhes, RGS2,
D2 receptors). The down-regulation of these latter proteins may be considered as a
potential self-defense mechanism to slow degeneration. For a majority of the striatal gene
products that have been identified so far, their function in the striatum is unknown and
their modifying effects on mHtt toxicity remain to be experimentally addressed. Focusing
on these striatal markers may contribute to a better understanding of HD pathogenesis,
and possibly the identification of novel therapeutic targets.
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INTRODUCTION
A SUMMARY OF WHAT IS HD
HD is a dominantly inherited disorder generally affecting young
adults. Symptoms include involuntary abnormal movements
(chorea, dyskinesia, dystonia), frontal cognitive deficits (e.g., per-
severation) and psychiatric disturbances (Harper, 1991; Walker,
2007). The disease is fatal approximately 15 years after the onset of
symptoms. There is no treatment available to slow the progression
of this devastating disorder.
HD is caused by amutation in theHTT gene encoding the pro-
tein huntingtin (Htt) that consists in a CAG triplet repeat expan-
sion translated into an abnormal poly-glutamine (polyQ) tract
within the N-terminal region of the protein (The-Huntington’s-
Disease-Collaborative-Research-Group, 1993). When consider-
ing cohorts of HD gene carriers, genetic studies showed that the
longer is the CAG repeat expansion the earlier the disease onsets.
However, there is a huge inter-individual variability in age of
onset (and nature) of symptoms for gene carriers with similar
CAG repeat numbers. Thus, apart from HD gene mutation,
many genetic, epigenetic and environmental factorsmay affect the
course of the disease (Sturrock and Leavitt, 2010). Deciphering
these factors and the underlying mechanisms affecting the onset
of this disease could constitute a real hope to find an efficacious
treatment to slow the disease.
The mutant protein is cleaved by many proteases leading
to the production of N-terminal fragments that form toxic
oligomers (Roze et al., 2008b). Eventually mutant Htt (mHtt)
forms intranuclear inclusions and somatodendritic aggregates
that also contain ubiquitin and represent a histopathological
hallmark of HD (Li and Li, 2004a).
Mechanisms of HD pathogenesis have been extensively studied
in the past 20 years, since the gene has been identified and cloned.
Thanks to many different genetic models (in cells, mice, rat, and
even monkeys) a large spectrum of cellular defects has been iden-
tified and could contribute to neurodegeneration. For this reason
the pathogenesis of HD is often considered multi-factorial. The
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polyQ expansion in mutated Htt (mHtt) produces a gain-of-
function that is toxic to neurons through several mechanisms.
One major early event in HD is the alteration of transcription
(Cha, 2007; Seredenina and Luthi-Carter, 2012). Importantly,
reduced transcription of Brain Derived Neurotrophic Factor
(BDNF), a major neurotrophic factor for striatal cells has been
found (Zuccato and Cattaneo, 2007). Axonal transport alter-
ations (Li and Li, 2004b; Roze et al., 2008b) leading to several
cellular disturbance, including defects in BDNF secretion and
transport (Gauthier et al., 2004) also contribute to neurodegen-
eration. Other alterations include intracellular signaling defects
(Borrell-Pages et al., 2006), deregulated of the proteasome path-
way (Finkbeiner and Mitra, 2008) and autophagy (Ravikumar
and Rubinsztein, 2006), perturbation of calcium homeostasis
leading to excitotoxicity (Cowan and Raymond, 2006; Raymond
et al., 2011), mitochondrial defects and oxidative stress (Damiano
et al., 2010).
In addition, the mutation in one allele is thought to pro-
duce a loss of function of wild type Htt (Cattaneo et al., 2005).
Indeed, htt is involved in a large variety of physiological cellu-
lar processes. It regulates vesicle transport through regulation of
molecular motors of the cytoskeleton, transcription of impor-
tant pro-survival factors (such a BDNF) by interacting with key
transcription factors and co-activators of transcription, cell divi-
sion, intracellular signaling and ATP production (Zuccato and
Cattaneo, 2014).
While wild type and mHtt protein are ubiquitously expressed
in the brain, degeneration primarily affects the striatum. The
contribution of striatal degeneration in motor and cognitive
symptoms is not totally understood but neuropathological studies
showed that striatal atrophy correlates with severity of symp-
toms (Myers et al., 1988). Recently, follow up of HD gene carriers
cohort using Magnetic Resonance Imaging (MRI) and Positron
Emission Tomography (PET) showed that even at presymp-
tomatic stages, the atrophy of the striatum is detectable and may
start even 10 years before onset of symptoms (Tabrizi et al., 2013).
Other brain regions may also be damaged at early stages, such
as the hypothalamus, and at later stages the cerebral cortex and
other regions also degenerate (for a review, Brouillet et al., 1999;
Petersen and Bjorkqvist, 2006). Thus, HD is not a selective stri-
atal disease. Many innovative studies discovered extra-striatal and
peripheral anomalies in HD animal models and for particular
studies in HD patients (Martin et al., 2008; Obeso et al., 2014).
However, the preferential striatal degeneration is an intriguing
characteristic of this illness, and the underlying mechanisms may
represent an important aspect of HD pathogenesis.
EXISTENCE OF POSSIBLE COMPENSATORY MECHANISMS IN HD
The existence of compensatory mechanisms in HD (as for other
neurodegenerative diseases) is probable. Possibly, the best cir-
cumstantial evidence for this is that althoughmHtt is expressed in
the brain of HD gene carriers since birth, degeneration and symp-
toms appear during adulthood (with the exception of long CAG
repeat expansion carriers who develop the disease during child-
hood) (Harper, 1991; Walker, 2007). Similarly in genetic animal
models, degeneration and symptoms occur in adult or aged ani-
mals (Menalled and Chesselet, 2002; Menalled, 2005). It has been
shown that when mHtt is expressed in striatal neurons at similar
levels for the same duration, its neurotoxic effects are significantly
higher in aged animals, as compared to young animals (Diguet
et al., 2009). The reason for this age-dependent phenomenon
is unknown but it indicates that neurons possess the ability to
partially counteract cellular stress induced by mHtt, a plasticity
mechanism that may be progressively lost with aging. The aim of
this review is not to cover all the possible compensatory mecha-
nisms that may occur in the HD brain, but to focus on those that
can be found in the striatum. However, a few examples of poten-
tial compensatory mechanisms that could be encountered in all
cell types can be given.
There likely exist compensatory mechanisms at whole human
brain level, to overcome cell dysfunction and/or neurodegener-
ation in the striatum of HD patients. For example, PET studies
showed that effective learning performance on motor sequence
learning tasks, normally associated with activation of the dorso-
lateral prefrontal cortex and the caudate nucleus, was not requir-
ing the same brain regions in presymptomatic HD (pre-HD)
patients and healthy volunteers (Feigin et al., 2006). In presymp-
tomatic HD gene carriers, ventral prefrontal and orbitofrontal
regions were used possibly via thalamic projections.
At cellular level, transient/reversible transcriptional and post-
transcriptional mechanisms may intervene to compensate for
cell suffering and degeneration pathways. For example, the loss
of expression of the kinase PKCδ (Rue et al., 2014) is likely a
compensatory mechanism. Indeed, the overexpression of PKCδ
enhances mHtt toxicity in vitro. On the contrary, the knock down
of PKCδ (using siRNA strategy or expression of a dominant nega-
tive form) significantly reduces mHtt effects. Interestingly the loss
of PKCδ seems to occur through an increased degradation of the
protein by neurons expressing mHtt (Rue et al., 2014).
Examples of potential compensatory mechanisms in HD can
be found in studies related to defects energy metabolism that are
thought to occur early in HD. Unexpectedly, recent experiments
show that an early increase in the levels of high energy phosphate
metabolites (ATP, phosphocreatine) can be found in the brain
of HD mouse models (Mochel et al., 2012a; Tkac et al., 2012).
Consistent with these observation in genetic models of HD,
dynamic measurements of brain phosphocreatine levels during
synaptic activation in HD patients using 31P NMR spectroscopy
also demonstrate abnormalities in the use of high energy phos-
phate metabolites (Mochel et al., 2012b). In R6/2 and Knock-in
111Qmousemodels, early biochemical changes indicate that neu-
rons tend to compensate by activating energy promoting cellular
pathways (Mochel et al., 2012a). In particular, possible compen-
satory changes occur at the post-translational levels, leading to
an increase in AMPK phosphorylation in HD mice, which could
activate pathways leading to a more efficient metabolism.
Large scale analyses trying to broadly identify mRNA and/or
protein expression changes provide a huge amount of informa-
tion from which potential compensatory mechanisms in HDmay
be discovered. A well-controlled proteomic analysis of brain of
R6/2 HD mice at different ages underlined that a number of pro-
teins display transient /biphasic expression changes rather than
an age-dependent progressive decline (Zabel et al., 2009). For
instance, the absolute expression of the mitochondrial complex
II subunit Ip (iron-sulfur), a key regulator of oxidative energy
metabolism which is neuroprotective against mHtt (Benchoua
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et al., 2006; Damiano et al., 2013), is early reduced in 2 week-
old R6/2 mice, but is found to be increased in 8 weeks old of these
mice and brings back at basal levels at 12 weeks old (Zabel et al.,
2009).
Changes in the expression levels (decreases and more rarely
increases) of mRNA in HD have been extensively explored in the
last decade (Seredenina and Luthi-Carter, 2012). These changes
may indicate two types of phenomena. On one hand, it indi-
cates primary defects of transcription inherent to the presence
of mHtt. In many cases, the direct interaction of mHtt with
proteins that are part of macromolecular complexes involved in
transcription regulation leads to a reduction of transcription and
reduced levels of a large spectrum of gene products (Seredenina
and Luthi-Carter, 2012). On the other hand, changes in mRNA
levels (or protein) may not be directly linked to a primary effect of
mHtt but could rather result from a physiological response engen-
dered by the cellular stress induced by toxic gain of function of
mHtt. Many expression changes identified in large scale analy-
ses have been studied with the hypothesis that they were causal
in HD pathogenesis. It is not always the case. Expression changes
can represent self-defense mechanisms. To differentiate between
the two above mentioned mechanisms, knock-down/knock-out
or overexpression/neuro-rescue experiments in HD models are
needed. It is beyond the scope of the present review to pro-
vide a detailed description of the gene products that have been
experimentally tested. Here we will limit our review to gene prod-
ucts that have deregulated expression and that are preferentially
expressed in the striatum. The review of the studies focused on
“striatal gene products” illustrates that in some cases, expression
changes may represent compensation or self-defense mechanisms
while in others they directly contribute to degeneration of striatal
neurons.
STUDYING THE PREFERENTIAL VULNERABILITY OF THE STRIATUM TO
IDENTIFY POTENTIAL MODIFIERS
Working hypothesis
The particular vulnerability of the striatum in HD likely resides
in its molecular complexity. Whether its particular vulnerability
depends on only one or a subset of gene products, acting together,
is unknown. Recent publications indicate that the experimental
knock-down or overexpression of only one striatal gene prod-
uct can significantly change the toxicity of muHtt in cell models
and mouse models. In one instance, a single nucleotide polymor-
phism in a striatal gene, ADORA2A (adenosine receptor 2a) has
been found to be associated with earlier onset of symptoms in
large cohorts of HD patients (Dhaenens et al., 2009). Thus, stri-
atal gene products can have a significant impact of HD. From a
therapeutic point of view, this indicates that acting on one sin-
gle target may be sufficient to alter the course of the disease.
Therefore, trying to decipher the complex mechanisms underly-
ing neurodegeneration in the striatum may help to more broadly
highlight important factors of neuronal dysfunction and death,
and to point potential therapeutic interventions for HD (Brouillet
et al., 2005; Thomas, 2006; Brochier et al., 2008; Mazarei et al.,
2010).
The study of these causal or compensatory changes in the stria-
tum in HDmay also help to better understand other neurological
diseases where the striatum is functionally affected (e.g., Wilson,
Parkinson, metabolic diseases, addiction, depression etc.).
The notion of striatal markers
The hypothesis that gene products preferentially expressed in the
striatum (or more generally particularities of this brain region)
could play an important role in the susceptibility of the MSN
to mHtt toxicity has been studied for many years. Hypotheses
related to particular properties of the MSN related to energy
metabolism/oxidative stress, or glutamate –related excitotoxicity,
and other types of neurotransmitter systems that could explain
striatal atrophy in HD where proposed in the 80’s and 90’s (for
a review, Brouillet et al., 1999). The most recent developments
of transcriptomic analysis led to a broader “without a priori”
approach of the working hypothesis that striatum vulnerability to
mHtt could reside in the expression of one or a subset of striatal
enriched gene products.
The notion of striatal marker stems on the contrast of expres-
sion between the striatum and other brain regions. Relatively
old studies identified striatal markers based on studies using in
situ hybridization, immunohistochemistry, and biochemistry (see
references in Desplats et al., 2006, for a number of validated stri-
atal markers). The identification of approximately 50 validated
markers took approximately two decades. In-depth transcrip-
tomic analyses using serial analysis of gene expression (SAGE)
further characterized the molecular complexity of the striatum
as compared with other brain regions in mice allowed for the
identification of a large list of “striatal markers” in wild type
mice (de Chaldee et al., 2003; Brochier et al., 2008; Mazarei
et al., 2010). This approach, based on the collection of polyA-
containing RNA, provided a ranking of the number of copies of
the different RNA species in different regions in the mouse brain.
Comparison between brain regions led to the identification of
gene products whose expression shows high enrichment in the
striatum. Known striatal markers were found, but many anno-
tated gene products whose function in the striatum is unknown
were also identified. Approximately, 100–150 striatal markers
can be listed, many of which have been cross-validated in dif-
ferent studies (de Chaldee et al., 2003; Desplats et al., 2006;
Brochier et al., 2008; Mazarei et al., 2010). Transcriptomic studies
using oligonucleotide array or RT-PCR showed that the magni-
tude of transcriptional changes in the striatum of HD mouse
models for these genes preferentially expressed in the striatum
was higher than that of ubiquitously expressed genes (Desplats
et al., 2006). In the SAGE studies by Brochier and collabo-
rators (Brochier et al., 2008), a number of gene products of
unknown neurobiological function showed reduced expression
in the striatum of R6/2 HD mice. Transcriptomic DNA array
data in HD models and HD brain show that amongst the RNAs
whose expression is deregulated, those coding for striatal mark-
ers are proportionally more frequently altered (Hodges et al.,
2006; Kuhn et al., 2007). Another study validated a number of
these striatal markers and identified potentially new ones that
were found to be deregulated in YAC128 HD mice (Mazarei
et al., 2010). Supplemental Table 1 indicates the striatal mark-
ers that have been well validated based on the studies quoted
above.
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Thus, the notion of striatal marker has evolved with the pro-
gression of the analytical methods. The criteria to decide whether
a gene product is “preferentially” expressed in the striatum
remains debatable. In most cases, the currently available public
databases (Allen Brain Atlas) providing gene products expres-
sion in the brain in mice and humans generally confirm that the
“striatal markers” identified in the studies described above have
preferential striatal expression. In general, the contrast of “striatal
specificity” in comparison to the somatosensory and motor cere-
bral cortex is in the range of 3–10-fold enrichment. If we were to
consider a lower contrast (a two-fold difference between cortex
and striatum for example), the list of striatal markers would be
much longer. In addition, it must be mentioned that some striatal
gene products, although referenced as “striatal markers” can have
stronger expression in other anatomically restricted brain regions
such as the hippocampus or some thalamic nuclei.
This review aims at providing a concise overview of the striatal
markers that have been experimentally assessed for their capacity
to modify mHtt toxicity. These markers have a large spectrum of
biological functions and the alteration of the expression levels in
HD is not a priori indicative of their role in striatal vulnerability.
The different striatal gene products that have been experimentally
studied for their capacity to change mHtt toxicity can be classified
as “protoxic,” “neuroprotective,” and “neutral.” In some instances,
the expression changes (up or down) suggest the existence of a
compensatory “self-defense” mechanism. We will also point to
the large list of the other striatal markers that remain to be fully
investigated to determine their potential role in HD.
POTENTIAL PROTOXIC STRIATAL GENE PRODUCTS
D2-R (Dopamine type 2 receptor)
The hypothesis that dopamine, which is at high concentrations in
the striatum compared to other brain areas, might play an impor-
tant role in the preferential vulnerability of the striatum in HD
has been suggested long time ago (Reynolds et al., 1998; Jakel and
Maragos, 2000).
Anatomically, MSNs expressing D2-R (D2 MSN) receive pref-
erentially inputs from the Pyramidal Track type (PT-type) cortical
neurons whose projects ipsilaterally to the striatum. This pref-
erential innervation is believed to release more glutamate which
could contribute to make D2 MSNs more vulnerable to excito-
toxicity (Reiner et al., 2003; Ballion et al., 2008). Many electro-
physiological evidences suggest that D2 MSNs are more excitable
than D1 MSNs (Cepeda et al., 2007; Kreitzer and Malenka, 2007)
partly because they display fewer primary dendrites (Gertler et al.,
2008). Electrophysiological recordings of D2MSNs show a higher
frequency of spontaneous excitatory post-synaptic currents (sEP-
SCs) than direct pathway. Moreover, D2 MSNs display large
membrane depolarizations rarely seen in direct pathway MSNs
(Cepeda et al., 2008) after the addition of GABAA receptor block-
ers inducing epileptic form activity in CPN (Galvan et al., 2012a).
Taken together, these evidences support the idea that D2-MSN is
a fertile ground to develop abnormal responses.
Studies performed in YAC128 HD mouse model conducted
at a presymptomatic age (1.5 months) and at symptomatic age
(12 months) revealed interesting findings concerning the indirect
pathways. At presymptomatic age, no differences were observed
in excitatory and inhibitory synaptic transmission compared to
WT. When the animals are symptomatic and become resistant to
excitotoxicity, the inhibitory transmission in YAC128 D2 MSNs
is greatly increased (Andre et al., 2011). This may indicate that
the indirect pathway is subject to compensatory mechanism in
HD, resulting in turn to the slowdown of excitatory glutamatergic
synapses in the striatum.
Whether these changes in D2 MSN are only related to D2-R
signaling is not known. Direct support for a causal role for DA
and D2-R in HD comes from the recent demonstration that the
toxicity of the N-terminal fragments of mHtt is potentiated by
dopamine in cells expressing mHtt exon 1 and transgenic HD
mouse models (Charvin et al., 2005; Cyr et al., 2006; Stack et al.,
2007; Benchoua et al., 2008). Dopamine modifies the formation
of Htt-containing aggregates in primary striatal neurons trans-
fected with exon 1 of Htt gene and exacerbates mHtt-induced
cell death (Charvin et al., 2005). Of interest, this effect involves
D2-R signaling, since dopamine effect is blocked by D2 antago-
nists (Charvin et al., 2005; Benchoua et al., 2006). Dopamine loses
its detrimental effect when neurons are prepared from D2 recep-
tor null mice (Charvin et al., 2005). Chronic blockade of the D2-R
with a selective antagonist significantly reduces death of MSN in a
lentiviral model of mHtt expression in rats (Charvin et al., 2008).
Possibly, this “protoxic” effect of dopamine through D2-R stimu-
lation may involve a reduction of the mitochondrial complex II, a
key regulator of energy metabolism in neurons (Benchoua et al.,
2008). D2-R stimulation increases mHtt toxicity in mouse stri-
atal neurons via, among others, the activation of JNK pathway
and activation of the Rho/ROCK-II pathway (Charvin et al., 2005;
Deyts et al., 2009).
Thus, the presence of D2-R onMSNmay render these neurons
more susceptible to HD. However, expression of these receptors
is down regulated early in HD as seen using biochemical experi-
ments and PET scans in patients (Antonini et al., 1998; Glass et al.,
2000). Whether this decrease is entirely caused by a direct regula-
tion of D2-R transcription by mHtt is unknown. It is conceivable
that this decrease is, at least in part, an attempt of MSN to reduce
cellular stress generated by mHtt.
D1-R (Dopamine type 1 receptor)
In line with a role of D2-R, D1-R may also be involved in the
vulnerability of the striatum. Stimulation of D1-R promotes the
aggregation of N-terminal fragments of mHtt and cell death in
cell line in culture (Robinson et al., 2008). The mechanisms are
unknown but a protoxic role for D1-R has been suggested to be
mediated by regulation of glutamatergic synapse and facilitation
of excitotoxicity (Tang et al., 2007). Supporting this view, exper-
iments in cells immortalized from knock-in HD mice (111Q)
showed that activation of D1-R exacerbates mHtt–induced cell
death (Paoletti et al., 2008). D1-R activation facilitates glutamate
receptor-mediated activation of the Ca2+-dependent protease cal-
pain that in turn cleaves Cyclin dependent kinase 5 (Cdk5).
Cleavage of Cdk5 activator p35 into p25 would be neurotoxic
to striatal neurons (Paoletti et al., 2008). As for D2-R, D1-R
expression being reduced in HD patients and HD models, this
may also be seen as a self-defense mechanism to reduce mHtt
toxicity.
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CalDAG-GEFI (a.k.a. RASGRP2, calcium and DAG-regulated guanine
nucleotide exchange factor I)
CalDAG-GEFI is a guanine-nucleotide exchange factors (GEFs)
activated by diacylglycerol (DAG) and Ca2+. CalDAG-GEFI has
substrate specificity for Rap1A, and was found to be enriched in
the basal ganglia (Kawasaki et al., 1998). This striatal gene product
has been rarely studied, and its neurobiological function is not
totally understood.
A pioneering study showed that expression of this gene prod-
uct may render striatal cells more vulnerable to mHtt (Crittenden
et al., 2010). Interesting, it was shown that striatal neurons of
R6/2 mice with the highest level of mHtt-containing aggregates
had the lowest levels of CalDAG-GEF. Since macroscopic aggre-
gates are thought to be neuroprotective since they sequester mHtt
toxic soluble oligomeric species, these results indicated that the
presence of high levels of CalDAG-GEF may lead to increased
levels of toxic species of mHtt in transgenic mice. Supporting
this view, knock-down of CalDAG-GEF in a brain slice model
of HD is neuroprotective against mHtt-induced neurodegen-
eration. The mechanisms underlying its “pro-toxic” properties
are not determined. One possibility is that it may inhibit Ras-
dependent activation of the Erk/MAP kinase cascade in striatal
neurons. Thus, its diminished expression in HD may allow “re-
activation” of the pro-survival Erk/MAP kinase pathway to block
mHtt toxicity (Crittenden et al., 2010).
RGS2 (Regulator of G-protein signaling 2)
The RGS2 protein is a member of the RGS family of proteins
that binds Gα subunits of heterotrimeric G proteins. RGS2 inter-
fere with Gαq and Gαi to reduce their rate of hydrolysis of GTP
to GDP and thus inhibits the signal transduction from GPCRs.
RGS2 play a key role in synaptic plasticity (Kehrl and Sinnarajah,
2002). RGS2 directly interacts with adenylyl cyclases to inhibit the
production of cAMP. RGS2 may also regulate GPCR-mediated
Akt signaling (Anger et al., 2007). RGS2 expression is reduced
in the HD brain and HD mouse models. Seredinina and col-
laborators studied whether the loss of RGS2 could exacerbate or
reduce neurodegeneration induced by overexpression of mHtt in
striatal neurons using lentiviral vectors (Seredenina et al., 2011).
Results showed that increased expression of RGS2 further aggra-
vates mHtt-induced neurodegeneration. Underlying mechanisms
of RGS2 protoxic effects are not fully deciphered but the authors
provided preliminary data indicating that they may implicate
regulation of Erk/MAP kinase signaling.
Rhes (a.k.a. RASD2, Ras homolog enriched in striatum)
Rhes is a small G-protein that displays striking enrichment in
the striatum and can regulate signaling through G-protein cou-
pled receptors (Falk et al., 1999; Vargiu et al., 2004; Mealer
et al., 2014). It has been described as a mediator of mHtt
cytotoxicity (Subramaniam et al., 2009), acting as a regulator
of SUMOylation. The presence of Rhes in MSN would favor
the accumulation of toxic oligomeric species of mHtt in the
cytoplasm. More recently, the deletion of Rhes has been found
neuroprotective in HD R6/1 mice (Baiamonte et al., 2013).
Rhes binds Beclin-1 and activates autophagy, a lysosomal
degradation pathway critical in aging and neurodegeneration
(Mealer et al., 2014). Activation of autophagy has been shown to
be neuroprotective in HD models (Ravikumar and Rubinsztein,
2006). Rhes-induced autophagy is inhibited by mHtt. The
restricted expression of Rhes and its effect on autophagy may
explain the selective striatal pathology and delayed onset of HD.
DGK (Diacylglycerol kinase)
The expression of DGK is increased in the striatum of R6/2
HD mice. Zhang and collaborators deciphered the potential role
that this increase may have in striatal degeneration/dysfunction
after having identified this kinase as a potential therapeutic tar-
get based on a screening of kinase inhibitors in a cellular models
expressing mHtt (Zhang et al., 2012). The inhibitor of DGK
(R59949) blocked induction of cell death pathways triggered by
serum withdrawal in knock-in (111Q/111Q) HD striatal cells.
Knockdown of all isoforms of DGK using siRNA strategy demon-
strated that selective inhibition of DGKε was responsible for the
neuroprotective effect of the inhibitor. Zhang and collaborators
found that knocking down DGK gene in a fly model of HD
was neuroprotective. Altogether these data indicate that increased
DGK in the striatum could contribute to striatal degeneration.
DGK increase could be considered as a protoxic event in HD
pathogenesis.
Calcineurin (or protein phosphatase 3, formerly known as protein
phosphatase 2B)
Since 1986, calcineurin has been identified by Goto as a marker
of neuronal degeneration in the striatum of HD patients (Goto
et al., 1986). Calcineurin has preferential expression in the stria-
tum and is downregulated in HD patients and mouse models of
HD (Xifro et al., 2009). Calcineurin dephosphorylates Htt at ser-
ine 421, inhibition of calcineurin restores axonal transport and
transport of BDNF vesicles (Pineda et al., 2009). It is known that
Htt phosphorylation is an important protective mechanism in
striatal neurons (Humbert et al., 2002). Phosphorylation of mHtt
at serine 421 promotes neuroprotection in HD, by restoring Htt
function and the transport of BDNF. Supporting the view that
reduced calcineurin may be neuroprotective in HD, increased Htt
phosphorylation can be produced by pharmacological inhibition
of calcineurin with the immunosuppressor FK506 (also known
as tacrolimus and fujimycine) (Pardo et al., 2006), or by overex-
pression of the regulators of calcineurin RCAN1-1L (Ermak et al.,
2009) leading to neuroprotective effects.
Thus, the reduction of calcineurin expression and function
would lead to a diminution of its activity, increasing phospho-
rylated state of key proteins, especially mHtt at S421, that activate
survival pathways. These mechanisms may be regarded as a com-
pensatory phenomenon that could retard the progression of
striatal degeneration.
PDE1B and PDE10A (Phosphodiesterase 1B and 10A)
Studies on phosphodiesterase (PDE) in HD models have shown
preferential reduction of the isoforms PDE1B and PDE10A in HD
models, while expression of other PDEs seems relatively main-
tained (Hebb et al., 2004). The loss is detected before onset of
symptoms in R6/2 and R6/1 models. Because, PDE regulates
levels of cAMP, which plays a key role in modulation of gene
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expression which is altered in HD, the effects of a treatment with
a PDE10 inhibitor has been studied in the R6/2 mouse model
of HD. Results showed that chronic pharmacological blockade
of PDE10 is neuroprotective and reverses a number of tran-
scriptomic anomalies in HD mice (Giampa et al., 2010). In line
with this, the characterization of the effects of a pharmacolog-
ical inhibition of PDE indirectly suggests that the reduction of
PDE activity in HD could lead to multiple effects: it up-regulates
cAMP-responsive element –dependent transcription, it down-
regulates HDAC4 (histone deacetylase 4) mRNA, and could acti-
vate Mitogen- and stress-activated kinase-1 (MSK1). These latter
effects should contribute to striatal neurons against mHtt toxic-
ity. Thus, the presence of PDE in striatal cells may be considered
protoxic, and its decrease in HD could be seen as a compen-
satory mechanism to counteract the effect of mHtt. Interestingly,
further inhibition of the enzyme may allow the triggering of neu-
roprotective pathway and as such may constitute an interesting
pharmacological therapy.
POTENTIAL NEUROPROTECTIVE STRIATAL GENE PRODUCTS
BCL11 (B-cell leukemia/lymphoma 11B)
B-cell leukemia/lymphoma 11B (Bcl11b) (a.k.a. CTIP2) is a tran-
scription factor that has been described to be a key gene for
differentiation of medium sized spiny neurons in the striatum.
Since MSN represent ∼95% of the neurons in the striatum,
Bcl11b likely possesses a central role that determines the archi-
tecture and organization of the striatum, and as such its function
is likely crucial in HD (Arlotta et al., 2008). Bcl11b mRNA levels
are reduced in the HD striatum. The overexpression of Bcl11b
has been found neuroprotective in cell models of HD in vitro
(Desplats et al., 2008). The direct interaction of Bcl11b with mHtt
and its possible sequestration in inclusions may further abolish
its capacity to regulate the expression of many striatal genes that
are crucial for the survival of MSN. In particular, there exists a
functional interaction between Bcl11b and BDNF. Chromatin-
immunoprecipitation experiment and sequencing (ChIP-seq)
indicated that Bcl11b is a regulator of the BDNF signaling path-
way (Tang et al., 2011). Thus, the loss of Bcl11b in the striatum
may lead to a striatal-selective cascade of events that could explain
the preferential vulnerability of MSNs against mHtt.
FOXP1 (Forkhead box protein P1)
FOXP1 is thought to be an important transcription factor regulat-
ing cell-cell interaction signaling. FOXP1 shows highly expression
in the striatum (Desplats et al., 2006, 2008). Its expression is reg-
ulated by Bcl11b. There exist overlaps between the genes that
are regulated by FOXP1 in normal neurons and the genes that
are deregulated in HD (Tang et al., 2012). No rescue or knock-
down experiments have been performed, but FOXP1 seems to
interact with mHtt and to be trapped in mHtt-containing aggre-
gates (Tang et al., 2012). Therefore, its reduced expression likely
contributes to the preferential vulnerability of the striatum inHD.
MSK-1 (Mitogen- and stress-activated kinase-1)
In healthy conditions, the mitogen- and stress-activated
kinase-1 (MSK-1), a striatum-enriched nuclear protein kinase
downstream Extracellular Regulated Kinase (ERK), promotes
activation of the transcriptional factor kappa-light-chain-
enhancer of activated B cells (NF-kappaB) signaling, inducing
c-Fos transcriptional activation important for immune and
inflammatory responses (Vermeulen et al., 2003). MSK-1 is
downregulated in R6/2 HD model mice and in caudate from
HD patients (Roze et al., 2008a). Overexpression of MSK-1 in
primary culture of striatal neurons expressing a short fragment
of mHtt is neuroprotective, whereas knockdown of MSK-1 is
protoxic. Interestingly Roze and collaborators found evidence
of ERK, Elk-1, and CREB nuclear activation in the striatum of
R6/2 mice. This suggested the existence of a possible self-defense
response in striatal neurons. However, this response appeared
to be blunted, since neither phosphorylation of histone H3
phosphorylation nor c-Fos activation were detected. Indeed,
loss of MSK-1 in the striatum in HD mice impeaches activated
ERK to produce its downstream effects on transcription. In
the normal brain, MSK-1 phosphorylates histone H3, CREB
and up-regulates peroxisome proliferator-activated receptor
co-activator-1α (PGC-1α), playing role in bioenergetic stability
in MSNs. The MSK-1 downregulation likely produces mito-
chondrial dysfunction rendering MSNs more susceptible to
mHtt. Consistent with this hypothesis, MSK-1 overexpression
in striatal neurons using lentiviral vectors was neuroprotective
against mHtt in mouse models of HD (Martin et al., 2011).
Therefore, because MSK-1 shows enrichment in the stria-
tum, its loss would contribute to render the striatum more
fragile in HD.
ADORA2 (Adenosine receptor type 2A)
A2A receptors (A2A-R), coded by the ADORA2A gene have a
highly enriched expression in the striatum. The expression of
A2A receptor is down regulated in the striatum of HD patients
(Glass et al., 2000) and in several HDmouse models (R6/2,N171-
82Q) (Menalled et al., 2000; Chou et al., 2005) These receptors
are located at the terminal of cortico-striatal pathway (presy-
naptic receptors) and in the D2-MSNs (post-synaptic receptors).
The mRNA level of A2A-R in the striatum is higher in the
striatum than in the cerebral cortex. These two types (pre- and
post-synaptic) seem to differ in their contribution to neurode-
generative process. Evidences in HD area suggest that activation
of presynaptic A2A-R is pro-toxic for MSNs by modulation of
glutamate release whereas activation of post-synaptic A2A-R are
protective (Popoli et al., 2007). Both agonists and antagonists
were proposed to treat HD symptoms. Interestingly, the A2A-R
agonist, CGS21680, produces an opposite effect inWT and symp-
tomatic R6/2 in slices. Field potentials (FP) were recorded with
and without NMDA and CGS21680. The NMDA toxicity is
observed by the only partial recovery after the FP stimulation.
The addition of CGS21680 increases NMDA-mediated toxic-
ity in WT MSNs whereas it decreases it in symptomatic R6/2
mice (Martire et al., 2007). Thus, it seems that complex reg-
ulatory mechanisms, possibly compensatory, involve A2A-R in
HD mice.
The chronic effect of the presence of A2A-R, especially
expressed at high level in MSN is not totally understood. Genetic
deletion of the ADORA2A gene precipitates motor symptoms
and death in HD mice expressing a short N-terminal fragment
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 295 | 6
Francelle et al. Compensatory mechanisms in the striatum in Huntington’s disease
of mHtt (Mievis et al., 2011a). In support of the hypothe-
sis that A2A-R may have an impact on the disease progres-
sion, a single genetic polymorphism in the ADORA2A gene
in HD patient can modify the age of onset (Dhaenens et al.,
2009). Thus, the loss of A2A-R may be detrimental. These
receptors are likely neuroprotective. However, it must be under-
scored that the exact contribution of presynaptic receptors
of the cortico-striatal pathway vs. the post-synaptic receptors
expressed by MSN in these experiments remains to be fully
elucidated.
CNR1 (Cannabinoid type 1 receptor)
The profound and early loss of striatal type 1 cannabinoid recep-
tors (CB1-R) in the striatum and projection area (substantia
nigra reticulate and globus pallidus externus) in HD has been
demonstrated by autoradiography studies on post-mortem brain
samples from patients at early stages as for the A2A-R (Glass et al.,
2000). Loss of CB1 binding sites have been confirmed in vivo by
PET studies in HD patients (Van Laere et al., 2010). Elegant stud-
ies demonstrated that genetic deletion/knockout of CB1 receptors
exacerbates the motor phenotype in HD mice (Blazquez et al.,
2011; Mievis et al., 2011b). The loss of CB1-R might be due
to direct transcriptional deregulation produced by mHtt (via
mHtt-induced deregulation of REST) (Blazquez et al., 2011)
but also may result from more complex mechanisms. Indeed,
exposure of immortalized striatal cells with endogenous cannabi-
noids produced an increase in CB1-R expression (Laprairie et al.,
2013). Treatment of HD striatal cells (Q111/Q111) with cannabi-
noid markedly increases CB1-R expression. Available results from
in vitro experiments indicate that the loss of CB1-R in HD would
lead to reduced levels of BDNF, which in turn should render
striatal cells more vulnerable to mHtt toxicity, possibly through
decreases in PGC-1α levels (Laprairie et al., 2013). However, a
convincing work recently performed in R6/2 HD mice showed
that only the presynaptic CB1-R at the cortico-striatal terminals
actually underlie the neuroprotective effects of the CB1-R agonists
in vivo (Chiarlone et al., 2014). Thus, CB1-R can be considered
as neuroprotective. However, the impact of the reduced striatal
expression of CB1-R in HD is uncertain.
SCN4B (Sodium channel beta 4b subunit)
SCN4b mRNA expression is down regulated in HD models and
HD patients (Oyama et al., 2006; Kuhn et al., 2007; Brochier et al.,
2008). Its reduced expression is more severe than that of other
sodium channel subunits (Oyama et al., 2006). The function
of this sodium channel subunit is unknown. The good correla-
tion between loss of its expression and progression of the disease
in R6/2 mice suggested a potential role in striatal vulnerabil-
ity. In line with this, SCN4b levels seem to be more reduced in
regions of the central nervous system that are the most affected by
mHtt expression. Interestingly, overexpression of SCN4b in neu-
rons in primary culture produces trophic effects characterized by
increased dendritic genesis (Oyama et al., 2006). Thus, SCN4b
may be a “neuroprotective” striatal marker whose reduced expres-
sion in HDmay contribute to the preferential degeneration of the
striatal in HD. However, its putative neuroprotective effect needs
to be directly assessed against mHtt toxicity.
STEP61(PTPN5 gene, striatal-enriched protein tyrosine
phosphatase 61)
Reduced expression of STEP61 mRNA has been found in HD
transgenic models and HD brain (Desplats et al., 2006). In differ-
ent mouse models (YAC1128, TET-HDH94, R6/1, and KI111) the
protein is reduced and its level of phosphorylation is increased,
which should further contribute to a reduction of its phos-
phatase activity (Saavedra et al., 2011; Gladding et al., 2014).
Convincing results indicate that the loss of STEP61 is globally
detrimental to MSN, although it may also partially represent a
compensatory mechanism trying to block excitotoxicity in stri-
atal cells. In R6/1 mice, whereas STEP protein levels are reduced
in young (excitotoxicity sensitive) mice, its levels of phospho-
rylation is much increased, leading to its further inactivation
(Saavedra et al., 2011). In line with this, intrastriatal injection
of a permeable and active form of SETP61 (TAT-STEP), could
increase the excitotoxic lesions produced by the NMDA receptor
agonist quinolinate. In addition, an increased cleavage of STEP61
has been observed, resulting from increased calpain activation
due to entry of Ca2+ through NMDA receptors. An accumu-
lation of the breakdown product STEP33 (inactive and unable
to dephosphorylate MAPK/p38) is associated with elevated p38
phosphorylation (Saavedra et al., 2011), which his detrimental
for cell survival. STEP dephosphorylates ERK, reducing its acti-
vation and pro-survival signals. There is an increased activation
of pro-survival MAPK/ERK1/2 signaling in older mice resistant
to excitotoxicity. In young YAC128CAG HD mice that are sensi-
tive to excitotoxicity, STEP61 levels have also been found reduced,
as STEP33 (Gladding et al., 2014). At later stage, when YAC128
mice become resistant to excitotoxicity, the loss of STEP61may be
associated with the induction of ERK1 (blocking excitotoxicity)
while maintaining activation of MAPK/p38 that favors cell death
pathways. These very interesting studies clearly show the existence
of complex “striatum-specific” compensatory mechanisms in HD
mice, and their evolution over time, possibly to block sequentially
mHtt toxicity.
Thus, the role of STEP61 in striatal vulnerability is ambiva-
lent. Its loss in HD may reduce excitotoxicity, consistent with a
neuroprotective compensatory mechanism. In this case STEP61
could be considered as a protoxic actor in MSN. However, its loss
also contributes to activateMAPK/p38 pathway. In this latter case,
STEP61 may be seen as a neuroprotective agent for MSNs.
ElK-1 (ETS-like gene 1)
In basal condition, Elk-1 is ubiquitously expressed in the brain,
but in HD mice models R6/1 and R6/2, and in immortalized HD
mouse (Q111/Q111) cells, Elk-1 has a higher protein expression
level and phosphorylation, and is found in the nucleus of the
MSNs of 30 weeks old R6/1 mice and 12 weeks old R6/2 mice.
Elk-1 does not co-localize with mHtt, which suggests a higher
transcriptional activity compared to WTmice (Roze et al., 2008a;
Anglada-Huguet et al., 2012). The authors suggested that the
change in Elk-1 expression may be a compensatory mechanism
to protect MSN in response to mHtt-induced stress.
Elk-1 is a member of a subfamily of proteins called ternary
complex factors (TCF). Elk-1 is a transcriptional activator,
as it interacts with serum response factor to bind jointly to
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serum response elements in the promoters of several immediate-
early genes (IEGs), such as c-fos and egr-1. In the CNS,
Elk-1 is activated by ERKs in response to neurotrophins and
neurotransmitters.
Anglada-Huguet et al. have shown that down-regulation of
Elk-1 by siRNAs produces caspase 3 cleavage and cell death in
immortalized HDmouse (Q111/Q111) cells, but not in wild-type
cells (Anglada-Huguet et al., 2012). Thus, the induction of Elk-1
expression in HDmay be considered to be a neuroprotective com-
pensatory mechanism. However, transcriptional activity at the
c-fos promoter was impaired in the striatum of R6/2 transgenic
mice, despite activation/phosphorylation of Elk-1 (Roze et al.,
2008a). As mentioned above, the reduction of MSK1 in R6/2 mice
may partially impair the impact of Elk-1 activation. Elk-1 can be
considered as an “inducible” striatal marker in HD, likely produc-
ing a neuroprotective self-defense mechanism. Further studies are
awaited to better understand how the increase in Elk-1 plays a role
in striatal degeneration at late stage in animal models of HD.
NEUTRAL STRIATAL MARKERS
Capucin (a.k.a. Tmem90a)
Capucin, a gene of unknown function is preferentially expressed
in the striatum (de Chaldee et al., 2003). Notably, lower capucin
mRNA levels have been detected in the R6/1 transgenic mouse
model of HD (Desplats et al., 2006), R6/2 and in primary cul-
tures of rat striatal neurons expressing a mutant fragment of
human Htt than in the corresponding controls (de Chaldee et al.,
2006). However, in vivo experiments showed that capucin over-
expression is not able to counterbalance mHtt-induced toxicity
in the striatum in a lentiviral mouse model of HD (Galvan et al.,
2012b). Mice that were knockout for capucin gene had similar
susceptibility to mHtt-induced toxicity as wild type age-matched
littermates. Size and number of ubiquitin-containing inclusion
produced by overexpression of mHtt is these mice were simi-
lar to those detected in wild type mice (Galvan et al., 2012b).
Capucin downregulation in HD mouse models could be a direct
consequence of the transcriptional dysfunction occurring in HD
without major consequence onMSN survival. Thus, capucin may
be considered as a “neutral” striatal gene.
Hippocalcin
Hippocalcin, a neuronal calcium sensor protein, is also known
as p23k. Although the physiological role of hippocalcin is not
completely understood, it is implicated in the regulation of neu-
ronal viability and plasticity. Evidences showed that hippocalcin
is important for the homeostasis of intracellular calcium levels
(Amici et al., 2009). Hippocalcin can protect hippocampal neu-
rons against excitotoxicity induced damage by enhancing Ca2+
extrusion and maintaining ideal intracellular Ca2+ levels (Masuo
et al., 2007).
The decreased expression of hippocalcin in different mouse
models of HD suggested a role of this protein in striatal vul-
nerability. Rudinskiy and collaborators studied this hypothesis
in primary culture of striatal neurons (Rudinskiy et al., 2009).
Hippocalcin was overexpressed using lentiviral vectors in neurons
that expressed mHtt (N-terminal fragments with 82 glutamine
repeat). Analysis of different outcomes related to degeneration
indicated that hippocalcin was not neuroprotective. In addition,
overexpression of hippocalcin did not protect neurons subjected
to mitochondrial dysfunction caused by 3-nitropropionic acid
or glutamate-induced excitotoxicity, two conditions inducing
increase in cytoplasmic Ca2+ concentrations (Rudinskiy et al.,
2009). Thus, hippocalcin may have deregulated expression, in
absence of major consequences in neuronal survival. In this case,
as capucin, hippocalcin may be seen as “neutral” striatal marker.
However, it cannot be excluded that hippocalcin could have an
effect in different HD models, including animal models that
express full length mHtt.
OTHER POSSIBLE PATHWAYS TO BE INVESTIGATED
Nowadays, the number of studies trying to decipher the func-
tions of this small number of striatal genes is limited. However,
these pioneering studies which tried to understand their roles
with regard to mHtt toxicity provided key results indicating
that possibly, they are regulators of cell survival, upstream mas-
ter gene/protein networks of neuronal survival (Figure 1). In
particular, deregulation of membrane receptors (D1-R, D2-R,
CB1-R, A2A-R, SCN4B) involved in neurotransmission in HD
could directly modulate cell survival processes through differ-
ent routes (e.g., MAP Kinase pathway, regulation of PGC1-α
etc.). How these different receptors act to positively or neg-
atively regulate striatal cell survival remains to be uncovered.
It is likely that, for the GPCR, their effects are related to the
activation of heterotrimeric G proteins leading to increased or
decreased cAMP levels but could also be mediated through other
FIGURE 1 | Schematic representation of the striatal markers that have
been experimentally studied as potential modifiers of mutant
huntingtin toxicity in HD. Green boxes symbolize markers that are
“neuroprotective.” Red boxes symbolize markers that are “protoxic.”
Expression changes in markers included in the dotted-line rectangle may
represent, at least in part, self-defense-mechanisms. Markers in gray boxes
would have altered expression without major consequences on mHtt. Note
that striatal gene modifiers have broad biological functions and cellular
localization, including neurotransmitters binding, intracellular signaling
(kinases and phosphatases), and transcription activators. The nucleus is
symbolized by the gray colored round form. MSK1 and Elk1 can be found in
the cytoplasm and upon activation translocate in the nucleus.
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pathways such as the endocytosis/β-arrestin-mediated pathway
and/or interaction of heterotrimeric subunits with transmem-
brane ion channels (Ritter and Hall, 2009). Increased cAMP
levels may be considered neuroprotective while reduction of
cAMP should be “protoxic.” It is likely that mechanisms con-
verging on cAMP level regulation are important for opposing
mHtt toxicity. Indeed PDE which reduce cAMP levels is consid-
ered to increase striatal cell vulnerability to mHtt (see below).
However, it is probable that the effects of striatal membrane
receptors on mHtt toxicity cannot be only explained according
to their inherent capability to change cAMP levels. For exam-
ple, D2-R and D1-R are thought to be coupled to different
α subunits (αi/o and αs/olf, leading, when stimulated sepa-
rately, to a reduction and decrease in cAMP levels respectively)
(Beaulieu and Gainetdinov, 2011), but both receptors seem to
increase mHtt toxicity. Downstream cAMP changes (and pos-
sible through independent mechanisms) the protoxic effects of
D2-R may involve inhibition of the pro-survival kinase Akt
(Marion et al., 2014) while D1-R effects may involve CDK5
(Paoletti et al., 2008). In line with these complex mechanisms,
CB1-R which decrease cAMP levels when stimulated alone, are
rather neuroprotective against mHtt through a mechanism that
remains to be elucidated. One possibility is that co-activation
of D2-R and CB1-R which increase cAMP so that the loss of
CB1-R in HD may result in reduced cAMP levels and a pro-
toxic effect which would depend on the presence of D2-R (Glass
and Felder, 1997). There also exist a number of very complex
cross talks between membrane receptors signaling in striatal
neurons that could participate to more complex/integrated bio-
logical effects when their stimulation occurs simultaneously. In
particular, receptors can heteromerize, which changes their intra-
cellular signaling impact. For example, D1-R/D2-R heteromers
act preferentially through Gαq changing signaling as compared to
each receptos separately. Another interesting example is related to
A2A-R/D2-R heteromers. The activation of A2A-R in these het-
eromers reduced the binding of dopamine on the D2-R (Ferre
et al., 2008). Reciprocally, stimulation of D2-R represses the acti-
vation of adenylyl cyclase by A2-R. Other pathways may also
be involved. For example, the activation of β-arrestin signal-
ing by A2A-R/D2-R heteromers is stronger and more transient
as compared to D2-R alone (Borroto-Escuela et al., 2011). In
summary, the mechanisms through which those different mem-
brane receptors act all together on mHtt toxicity (as causal factors
or as key actors of compensatory/self-defense mechanisms) are
largely unknown but likely involve extremely complex/integrated
signaling.
Similarly cytoplasmic signaling proteins (PDE, MSK1,
STEP61, DGK) can also act upstream or downstream master
regulators of cell survival (CREB, MAPK/Erk1). Other stri-
atal markers seem to be involved in molecular steps between
membrane receptor signaling and downstream cytoplasmic
effectors. This is the case for RGS2 and CalDAG-GEF1. Other
striatal markers may not act directly on signaling processes
regulating transcription or survival. Indeed, it is likely that some
markers, such as Rhes, may involve key cellular “housekeeping”
mechanisms such as SUMOylation of proteins and autophagy.
Finally, Bcl11b and FOXP1 are good examples of striatal marker
that can be directly implicated in the regulation of transcription,
and the inherent state of differentiation of MSN.
The study of the role of striatal markers in striatal vulnerabil-
ity in HD suggests that these gene products, likely associated with
highly specific neurobiological functions (and as such they are
markers of highly differentiated non-dividing cells), may be, on
the one hand, the most vulnerable targets of mHtt-induced tran-
scription deregulations and, on the other hand, key “switches” of
striatal adaptive changes, that may be considered as self-defense
mechanisms.
How these different striatal markers functionally interact each
other remains to be precisely assessed. It is quite obvious that cur-
rently the puzzle is not complete and that many more actors are
involved in the vulnerability of the striatum. Indeed, beyond the
few striatal markers that have been reviewed above, many oth-
ers may also act as modifiers of mHtt. When considering striatal
markers with relatively stringent criteria (see paragraph above),
it clearly appears that only a small proportion of striatal mark-
ers has been experimentally studied. It is beyond the scope of this
review to provide extensive speculations on every striatal marker
that have never been studied in the context of HD research.
However, it is worthmentioning that many of them, which abnor-
mal expression in the striatum of HD patients have been observed
long ago, have never been studied for their capacity to mod-
ify mHtt toxicity. For example, neurotensin, whose expression
is high in the striatum as compared to other brain regions, has
been found abnormally increased in the HD striatum (Nemeroff
et al., 1983). Many newly identified striatal markers have been
found deregulated in HD mouse models (Brochier et al., 2008;
Mazarei et al., 2010). For example, the upregulation of IDO-1
(indoleamine 2,3-dioxygenase) in YAC128 HD mice may be seen
as a risk factor for striatal cells, since deletion of IDO-1 pro-
tects the striatum against excitotoxicity (Mazarei et al., 2013b).
Since kynurenine pathway likely plays a role in HD pathogenesis
(Thevandavakkam et al., 2010), it is possible that IDO-1 is a mod-
ifier of mHtt toxicity (Mazarei et al., 2013a). This remains to be
further assessed.
CONCLUSION
It is very difficult to know whether a change in expression of a
given striatal marker in HD represents a compensatory mecha-
nism, and/or a phenomenon that will contribute to striatal degen-
eration. This question needs to be experimentally addressed.
However, all the gene products that have not yet been explored
represent a pool of potential candidate modifiers of mHtt, rele-
vant to striatal vulnerability. Our group and others are currently
testing the effects of many newly identified striatal markers of
unknown biological functions. Preliminary observations indicate
that a majority of them are neuroprotective or protoxic modifiers
of mHtt in cell and mouse models. As such, they could represent
innovative therapeutic targets. Promoting the activity of the neu-
roprotective markers or blocking the activity of the protoxic gene
products could help to slow the progression of symptoms and
degeneration in HD. In addition, since a majority of these stri-
atal markers have ill-defined neurobiological functions, research
focused on these striatal gene products could be a unique oppor-
tunity to better define the molecular and functional complexity of
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the striatum, a brain region which is central stage in a broad spec-
trum of motor and cognitive functions and is likely implicated in
different neurological and psychiatric illnesses.
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